newsfilter
← Latest News
GlobeNewswire·

Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates

Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral dosing First